Thomas Edmund Cope
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thomas Edmund Cope has a total of 380 co-authors. Here are the top co-authors by number of shared publications:
- James Benedict Rowe
University of Cambridge
28 shared publications - John Tiernan O'Brien
Department of Psychiatry, University of Cambridge, UK
11 shared publications - Luca Passamonti
Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
11 shared publications Karalyn Patterson
Cambridge University Hospitals, Cambridge, UK; MRC Cognition and Brain Sciences Unit, Cambridge, UK
9 shared publications- Timothy Rittman
Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
9 shared publications - William Richard Bevan-Jones
University of Cambridge, Cambridge UNITED KINGDOM
9 shared publications
Latest Publications
- Open Access
Multi-centre validation of MELD-graph for automated focal cortical dysplasia detection using 7T compared to paired 3T MRI
Background: Software tools can support MRI diagnosis of focal cortical dysplasias (FCDs) – subtle, surgically-treatable lesions that underlie drug-resistant focal epilepsy (DRFE). MELD-graph, a widely used open-source tool combining surface-based morphometry with a convolutional neural network, was developed using 1.5T and 3T MRI data. 7T MRI is increasingly used for lesion detection in DRFE. This study investigated whether MELD-graph is robust to domain shift at 7T. Methods: We collated paired 3T and 7T T1-weighted MRI, and FLAIR where available, from 23 patients with FCD (6 histologically-verified, 17 identified radiologically) and 39 healthy controls at four epilepsy centres. Manual lesion labels were used as ground truth. MELD-graph was run on 3T images, on 7T images with the default pipeline, and on 7T images with adaptations for 7T MRI (SPM bias-field correction, SynthStrip skull-stripping, sub-millimetric FreeSurfer reconstruction), with and without ComBat harmonisation. FCD detection performance and surface morphometry features were compared. Results: Sensitivity for FCD detection was 65% (15/23) at 3T, 48% (11/23) for 7T default and 52% (12/23) for 7T adapted, with Combat harmonisation. Among radiologically 3T-negative patients, 2/8 were detected at 3T and 3/8 at 7T; and among histologically confirmed FCD, 3/6 at 3T and 1/6 at 7T. Specificity was significantly lower at 7T (default 39%, adapted 45%) than 3T (76%). False-positives predominantly occurred in the basal temporal lobes. ComBat harmonisation improved specificity in all conditions and largely compensated for field-strength dependent differences in surface morphometry features. Adding FLAIR at 7T increased false-positive predictions. Conclusion: Sensitivity is comparable but specificity of MELD-graph is lower at 7T compared to 3T. Adaptations for 7T MRI can reduce segmentation errors but do not significantly improve FCD detection, while harmonisation improves performance. The adapted pipeline is released open-source. 7T MELD-graph outputs may inform radiologist review in challenging cases but require cautious interpretation.
Open AccessMulti-centre validation of MELD-graph for automated focal cortical dysplasia detection using 7T compared to paired 3T MRI
Background: Software tools can support MRI diagnosis of focal cortical dysplasias (FCDs) – subtle, surgically-treatable lesions that underlie drug-resistant focal epilepsy (DRFE). MELD-graph, a widely used open-source tool combining surface-based morphometry with a convolutional neural network, was developed using 1.5T and 3T MRI data. 7T MRI is increasingly used for lesion detection in DRFE. This study investigated whether MELD-graph is robust to domain shift at 7T. Methods: We collated paired 3T and 7T T1-weighted MRI, and FLAIR where available, from 23 patients with FCD (6 histologically-verified, 17 identified radiologically) and 39 healthy controls at four epilepsy centres. Manual lesion labels were used as ground truth. MELD-graph was run on 3T images, on 7T images with the default pipeline, and on 7T images with adaptations for 7T MRI (SPM bias-field correction, SynthStrip skull-stripping, sub-millimetric FreeSurfer reconstruction), with and without ComBat harmonisation. FCD detection performance and surface morphometry features were compared. Results: Sensitivity for FCD detection was 65% (15/23) at 3T, 48% (11/23) for 7T default and 52% (12/23) for 7T adapted, with Combat harmonisation. Among radiologically 3T-negative patients, 2/8 were detected at 3T and 3/8 at 7T; and among histologically confirmed FCD, 3/6 at 3T and 1/6 at 7T. Specificity was significantly lower at 7T (default 39%, adapted 45%) than 3T (76%). False-positives predominantly occurred in the basal temporal lobes. ComBat harmonisation improved specificity in all conditions and largely compensated for field-strength dependent differences in surface morphometry features. Adding FLAIR at 7T increased false-positive predictions. Conclusion: Sensitivity is comparable but specificity of MELD-graph is lower at 7T compared to 3T. Adaptations for 7T MRI can reduce segmentation errors but do not significantly improve FCD detection, while harmonisation improves performance. The adapted pipeline is released open-source. 7T MELD-graph outputs may inform radiologist review in challenging cases but require cautious interpretation.
- Open Access
Automated hippocampal sclerosis detection, using AID-HS, shows robust performance across multi-centre paired 7T and 3T MRI
Background: Hippocampal sclerosis (HS) is a common cause of drug-resistant focal epilepsy (DRFE) and amenable to neurosurgical treatment. Detection relies on MRI but can be challenging. 7 Tesla (T) ultra-high field MRI and automated MRI post-processing tools have independently been shown to improve radiological diagnosis of HS. However, combining these approaches remains underexplored. This study evaluated whether AID-HS, a tool for HS detection developed using 3T MRI, generalises to 7T MRI data. Methods: We collated a dataset of paired 3T and 7T T1-weighted MRI from four epilepsy centres, including 23 patients with HS, 39 healthy controls, and 23 individuals with focal cortical dysplasia as disease controls. Histopathology served as the gold standard for defining HS where available (n=7), otherwise radiological findings (n=16). AID-HS was applied to images acquired at both field strengths, and sensitivity and specificity for detection and lateralisation of HS were compared. Additionally, agreement of hippocampal features across 3T and 7T was evaluated. Results: We found no evidence of a difference in performance of AID-HS between 3T and 7T. Sensitivity for detection of unilateral HS was 63% (12/19) at 3T and 68% (13/19) at 7T (McNemar’s exact test p=1.0). Specificity in controls was 97% (60/62) at 3T and 100% (62/62) at 7T (p=0.5). Bilateral HS was correctly flagged in 3 of 4 cases using feature-based criteria, with high specificity in controls. Quantitative hippocampal features showed moderate to good agreement across field strengths (ICC 0.70 to 0.98), with small differences observed for volume and thickness estimates. Conclusion: AID-HS provides robust detection and lateralisation of HS across multiple 7T MRI centres, highlighting its potential to enhance lesion detection. Future work is needed to investigate whether models trained on 7T data can leverage the improved image quality for further gains in HS detection performance.
Open AccessAutomated hippocampal sclerosis detection, using AID-HS, shows robust performance across multi-centre paired 7T and 3T MRI
Background: Hippocampal sclerosis (HS) is a common cause of drug-resistant focal epilepsy (DRFE) and amenable to neurosurgical treatment. Detection relies on MRI but can be challenging. 7 Tesla (T) ultra-high field MRI and automated MRI post-processing tools have independently been shown to improve radiological diagnosis of HS. However, combining these approaches remains underexplored. This study evaluated whether AID-HS, a tool for HS detection developed using 3T MRI, generalises to 7T MRI data. Methods: We collated a dataset of paired 3T and 7T T1-weighted MRI from four epilepsy centres, including 23 patients with HS, 39 healthy controls, and 23 individuals with focal cortical dysplasia as disease controls. Histopathology served as the gold standard for defining HS where available (n=7), otherwise radiological findings (n=16). AID-HS was applied to images acquired at both field strengths, and sensitivity and specificity for detection and lateralisation of HS were compared. Additionally, agreement of hippocampal features across 3T and 7T was evaluated. Results: We found no evidence of a difference in performance of AID-HS between 3T and 7T. Sensitivity for detection of unilateral HS was 63% (12/19) at 3T and 68% (13/19) at 7T (McNemar’s exact test p=1.0). Specificity in controls was 97% (60/62) at 3T and 100% (62/62) at 7T (p=0.5). Bilateral HS was correctly flagged in 3 of 4 cases using feature-based criteria, with high specificity in controls. Quantitative hippocampal features showed moderate to good agreement across field strengths (ICC 0.70 to 0.98), with small differences observed for volume and thickness estimates. Conclusion: AID-HS provides robust detection and lateralisation of HS across multiple 7T MRI centres, highlighting its potential to enhance lesion detection. Future work is needed to investigate whether models trained on 7T data can leverage the improved image quality for further gains in HS detection performance.
- 27 May 2025
- Published by BMJ in Practical Neurology
- Vol. 26 (1) , 37-42
Treating anxiety and depression in people with epilepsy
The major barriers to detecting, diagnosing and treating depression in the epilepsy clinic are a lack of confidence and a lack of time. Patients with epilepsy have a significantly increased risk of anxiety and depression, and an increased risk of suicide, so conversations about mood should be considered as routine as conversations about SUDEP (sudden unexpected death in epilepsy). Neurologists should feel confident in prescribing serotonin reuptake inhibitors and should know how to refer to local next-stage mental health services if required. Access to psychological well-being services is better than most people are aware of, and self-referral is possible. We would encourage neurologists to strongly consider mental health when prescribing antiseizure medications, especially levetiracetam, and to disseminate such considerations to acute medical, anaesthetic and neurosurgical colleagues. We provide some simple, practical advice to equip neurologists and epilepsy nurses to talk to patients about their mental health and to take initial steps towards treatment.
- 27 May 2025
- Published by BMJ in Practical Neurology
- Vol. 26 (1) , 37-42
Treating anxiety and depression in people with epilepsy
The major barriers to detecting, diagnosing and treating depression in the epilepsy clinic are a lack of confidence and a lack of time. Patients with epilepsy have a significantly increased risk of anxiety and depression, and an increased risk of suicide, so conversations about mood should be considered as routine as conversations about SUDEP (sudden unexpected death in epilepsy). Neurologists should feel confident in prescribing serotonin reuptake inhibitors and should know how to refer to local next-stage mental health services if required. Access to psychological well-being services is better than most people are aware of, and self-referral is possible. We would encourage neurologists to strongly consider mental health when prescribing antiseizure medications, especially levetiracetam, and to disseminate such considerations to acute medical, anaesthetic and neurosurgical colleagues. We provide some simple, practical advice to equip neurologists and epilepsy nurses to talk to patients about their mental health and to take initial steps towards treatment.
- Open Access
Parallel transmit 7 T MRI for adult epilepsy pre‐surgical evaluation
Objective: To implement parallel transmit (pTx) 7T magnetic resonance imaging (MRI) in the pre‐surgical evaluation of 3T‐negative patients with drug‐resistant focal epilepsy, and to compare quality to conventional single transmit (specifically, circularly polarized [CP]) 7T MRI. Methods: We implemented a comparative protocol comprising both pTx and CP 7T MRI in consecutive adult candidates for epilepsy surgery who had negative or equivocal 3T MRI imaging. Here we report the outcomes from the first 31 patients. We acquired pTx and CP T 1 , T 2 , fluid‐attenuated inversion recovery (FLAIR) and edge‐enhancing gradient echo (EDGE) images, all in the same three‐dimensional (3D) 0.8 mm isotropic space. Two‐dimensional (2D) high‐resolution T 2 and T 2 *‐weighted sequences were acquired only in CP mode due to current technological limitations. Two neuroradiologists, a neurologist, and a neurosurgeon made independent, blinded quality and preference ratings of pTx vs CP images. Quantitative methods were used to assess signal dropout. Results: 7T revealed previously‐unseen structural lesions in nine patients (29%), confirmed 3T‐equivocal lesions in four patients (13%), and disproved 3T‐equivocal lesions in four patients (13%). Lesions were better visualized on pTx than CP in 57% of cases, and never better visualized on CP. Clinical management was altered by 7T in 18 cases (58%). Nine cases were offered surgical resection and one laser interstitial thermal therapy (LITT). Three cases were removed from the surgical pathway because of bilateral or extensive lesions. Five cases were offered stereo‐electroencephalography (sEEG) with better targeting (in three because the 7T lesion was deemed equivocal by the multi‐disciplinary team (MDT), and in two because the lesion was extensive). Blinded comparison confirmed significantly better overall quality of pTx FLAIR images ( F (2, 184) = 13.7, p = 2.88 × 10 −6 ), whereas pTx MP2RAGE images were subjectively non‐inferior and had improved temporal lobe coverage with quantitatively less signal drop‐out. Significance: pTx‐7T is implementable in a clinical pathway, changed management in 58% of patients where 3T + FDG‐PET had not enabled resection, and is superior to single transmit 7T MRI.
Open AccessParallel transmit 7 T MRI for adult epilepsy pre‐surgical evaluation
Objective: To implement parallel transmit (pTx) 7T magnetic resonance imaging (MRI) in the pre‐surgical evaluation of 3T‐negative patients with drug‐resistant focal epilepsy, and to compare quality to conventional single transmit (specifically, circularly polarized [CP]) 7T MRI. Methods: We implemented a comparative protocol comprising both pTx and CP 7T MRI in consecutive adult candidates for epilepsy surgery who had negative or equivocal 3T MRI imaging. Here we report the outcomes from the first 31 patients. We acquired pTx and CP T 1 , T 2 , fluid‐attenuated inversion recovery (FLAIR) and edge‐enhancing gradient echo (EDGE) images, all in the same three‐dimensional (3D) 0.8 mm isotropic space. Two‐dimensional (2D) high‐resolution T 2 and T 2 *‐weighted sequences were acquired only in CP mode due to current technological limitations. Two neuroradiologists, a neurologist, and a neurosurgeon made independent, blinded quality and preference ratings of pTx vs CP images. Quantitative methods were used to assess signal dropout. Results: 7T revealed previously‐unseen structural lesions in nine patients (29%), confirmed 3T‐equivocal lesions in four patients (13%), and disproved 3T‐equivocal lesions in four patients (13%). Lesions were better visualized on pTx than CP in 57% of cases, and never better visualized on CP. Clinical management was altered by 7T in 18 cases (58%). Nine cases were offered surgical resection and one laser interstitial thermal therapy (LITT). Three cases were removed from the surgical pathway because of bilateral or extensive lesions. Five cases were offered stereo‐electroencephalography (sEEG) with better targeting (in three because the 7T lesion was deemed equivocal by the multi‐disciplinary team (MDT), and in two because the lesion was extensive). Blinded comparison confirmed significantly better overall quality of pTx FLAIR images ( F (2, 184) = 13.7, p = 2.88 × 10 −6 ), whereas pTx MP2RAGE images were subjectively non‐inferior and had improved temporal lobe coverage with quantitatively less signal drop‐out. Significance: pTx‐7T is implementable in a clinical pathway, changed management in 58% of patients where 3T + FDG‐PET had not enabled resection, and is superior to single transmit 7T MRI.
- Open Access
Parallel transmit improves 7T MRI adult epilepsy pre-surgical evaluation
Objective: To implement parallel transmit (pTx) 7T MRI in the pre-surgical evaluation of patients with drug resistant focal epilepsy, and to compare quality and diagnostic yield to conventional single transmit (specifically, circularly polarised, CP) 7T MRI. Methods: We implemented a comparative protocol comprising both pTx and CP 7T MRI in consecutive adult candidates for epilepsy surgery who had negative or equivocal 3T MRI imaging. Here we report the outcomes from the first 31 patients. We acquired pTx and CP T 1 , T 2 , FLAIR and EDGE images, all in the same 3D 0.8mm isotropic space. 2D high-resolution T 2 and T 2 *-weighted sequences were acquired only in CP mode due to current technological limitations. Two neuroradiologists, a neurologist and a neurosurgeon made independent, blinded quality and preference ratings of pTx vs CP images. Quantitative methods were used to assess signal dropout. Results: Blinded comparison confirmed significantly better overall quality of pTx FLAIR images (F(2,184)=13.7, p=2.88×10 -6 ), while pTx MP2RAGE images were subjectively non-inferior and had improved temporal lobe coverage with quantitatively less signal drop-out. 7T-pTx revealed previously-unseen structural lesions in 9 patients (29%), confirmed 3T-equivocal lesions in 4 patients (13%), and disproved 3T-equivocal lesions in 4 patients (13%). Lesions were better visualised on pTx than CP in 57% of cases, and never better visualised on CP. Clinical management was altered by pTx-7T in 18 cases (58%). 9 cases were offered surgical resection and 1 LITT. 3 cases were removed from the surgical pathway because of bilateral or extensive lesions. 5 cases were offered sEEG with better targeting (in 3 because the 7T lesion was deemed equivocal by the MDT, and in 2 because the lesion was extensive). Significance: Parallel transmit 7T MRI is implementable in a clinical pathway, is superior to single transmit 7T MRI, and changed management in 58% of patients scanned. Key points: We scanned 31 patients with parallel transmit and conventional 7T MRI, finding previously-unreported structural lesions in 9 patients (29% of cases). In 13% of cases pTx 7T MRI showed that an equivocal lesion at 3T MRI was likely significant. In 13% of cases pTx 7T MRI showed that an equivocal lesion at 3T MRI could be disregarded. Both qualitative and quantitative quality assessments indicate superiority of pTx images over CP. Future clinical implementations of 7T MRI for epilepsy should utilise parallel transmit where possible.
Open AccessParallel transmit improves 7T MRI adult epilepsy pre-surgical evaluation
Objective: To implement parallel transmit (pTx) 7T MRI in the pre-surgical evaluation of patients with drug resistant focal epilepsy, and to compare quality and diagnostic yield to conventional single transmit (specifically, circularly polarised, CP) 7T MRI. Methods: We implemented a comparative protocol comprising both pTx and CP 7T MRI in consecutive adult candidates for epilepsy surgery who had negative or equivocal 3T MRI imaging. Here we report the outcomes from the first 31 patients. We acquired pTx and CP T 1 , T 2 , FLAIR and EDGE images, all in the same 3D 0.8mm isotropic space. 2D high-resolution T 2 and T 2 *-weighted sequences were acquired only in CP mode due to current technological limitations. Two neuroradiologists, a neurologist and a neurosurgeon made independent, blinded quality and preference ratings of pTx vs CP images. Quantitative methods were used to assess signal dropout. Results: Blinded comparison confirmed significantly better overall quality of pTx FLAIR images (F(2,184)=13.7, p=2.88×10 -6 ), while pTx MP2RAGE images were subjectively non-inferior and had improved temporal lobe coverage with quantitatively less signal drop-out. 7T-pTx revealed previously-unseen structural lesions in 9 patients (29%), confirmed 3T-equivocal lesions in 4 patients (13%), and disproved 3T-equivocal lesions in 4 patients (13%). Lesions were better visualised on pTx than CP in 57% of cases, and never better visualised on CP. Clinical management was altered by pTx-7T in 18 cases (58%). 9 cases were offered surgical resection and 1 LITT. 3 cases were removed from the surgical pathway because of bilateral or extensive lesions. 5 cases were offered sEEG with better targeting (in 3 because the 7T lesion was deemed equivocal by the MDT, and in 2 because the lesion was extensive). Significance: Parallel transmit 7T MRI is implementable in a clinical pathway, is superior to single transmit 7T MRI, and changed management in 58% of patients scanned. Key points: We scanned 31 patients with parallel transmit and conventional 7T MRI, finding previously-unreported structural lesions in 9 patients (29% of cases). In 13% of cases pTx 7T MRI showed that an equivocal lesion at 3T MRI was likely significant. In 13% of cases pTx 7T MRI showed that an equivocal lesion at 3T MRI could be disregarded. Both qualitative and quantitative quality assessments indicate superiority of pTx images over CP. Future clinical implementations of 7T MRI for epilepsy should utilise parallel transmit where possible.
- Open Access
- 24 August 2024
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 121, 217-225
Does epilepsy differentially affect different types of memory?
- 24 August 2024
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 121, 217-225
Open AccessDoes epilepsy differentially affect different types of memory?
- Open Access
- 22 May 2024
- Published by Springer Nature in Memory & Cognition
- Vol. 53 (1) , 428-437
Drawing from name in semantic dementia reveals graded object knowledge representations in anterior temporal lobe
Semantic dementia (SD) is characterized by progressive impairment in conceptual knowledge due to anterior temporal lobe (ATL) neurodegeneration. Extended neuropsychological assessments can quantitatively demonstrate the semantic impairment, but this graded loss of knowledge can also be readily observed in the qualitative observation of patients’ recall of single concepts. Here, we present the results of a simple task of object drawing-from-name, by patients with SD (N = 19), who have isolated atrophy of the ATL bilaterally. Both cross-sectionally and longitudinally, patient drawings demonstrated a pattern of degradation in which rare and distinctive features (such as the hump on a camel) were lost earliest in disease course, and there was an increase in the intrusion of prototypical features (such as the typical small ears of most mammals on an elephant) with more advanced disease. Crucially, patient drawings showed a continuum of conceptual knowledge loss rather than a binary ‘present’ or ‘absent’ state. Overall, we demonstrate that qualitative evaluation of line drawings of animals and objects provides fascinating insights into the transmodal semantic deficit in SD. Our results are consistent with a distributed-plus-hub model of semantic memory. The graded nature of the deficit in semantic performance observed in our subset of longitudinally observed patients suggests that the temporal lobe binds feature-based semantic attributes in its central convergence zone.
- 22 May 2024
- Published by Springer Nature in Memory & Cognition
- Vol. 53 (1) , 428-437
Open AccessDrawing from name in semantic dementia reveals graded object knowledge representations in anterior temporal lobe
Semantic dementia (SD) is characterized by progressive impairment in conceptual knowledge due to anterior temporal lobe (ATL) neurodegeneration. Extended neuropsychological assessments can quantitatively demonstrate the semantic impairment, but this graded loss of knowledge can also be readily observed in the qualitative observation of patients’ recall of single concepts. Here, we present the results of a simple task of object drawing-from-name, by patients with SD (N = 19), who have isolated atrophy of the ATL bilaterally. Both cross-sectionally and longitudinally, patient drawings demonstrated a pattern of degradation in which rare and distinctive features (such as the hump on a camel) were lost earliest in disease course, and there was an increase in the intrusion of prototypical features (such as the typical small ears of most mammals on an elephant) with more advanced disease. Crucially, patient drawings showed a continuum of conceptual knowledge loss rather than a binary ‘present’ or ‘absent’ state. Overall, we demonstrate that qualitative evaluation of line drawings of animals and objects provides fascinating insights into the transmodal semantic deficit in SD. Our results are consistent with a distributed-plus-hub model of semantic memory. The graded nature of the deficit in semantic performance observed in our subset of longitudinally observed patients suggests that the temporal lobe binds feature-based semantic attributes in its central convergence zone.
- Open Access
Peripheral inflammatory markers relate to central inflammation and survival in syndromes associated with frontotemporal lobar degeneration
Neuroinflammation is an important pathogenic mechanism in many neurodegenerative diseases, including those caused by frontotemporal lobar degeneration (FTLD). There is a pressing need for scalable and mechanistically relevant blood markers of inflammation to facilitate drug development and experimental medicine. We assessed inflammatory profiles of serum cytokines from 214 patients with FTLD-associated syndromes (behavioural and language variants of frontotemporal dementia, progressive supranuclear palsy, corticobasal syndrome). We tested the association with brain microglial activation (by positron emission tomography) and survival. A pro-inflammatory profile across the FTLD spectrum (including TNF-α, TNF-R1, M-CSF, IL-17A, IL-12, IP-10 and IL-6) differentiated patients (all syndromes) from controls. A higher pro-inflammatory profile scores was associated with higher microglial activation in frontal and brainstem regions, and with lower survival. Blood-based markers of inflammation could increase the scalability and access to neuroinflammatory assessment of people with dementia, to facilitate clinical trials and experimental medicine studies.
Open AccessPeripheral inflammatory markers relate to central inflammation and survival in syndromes associated with frontotemporal lobar degeneration
Neuroinflammation is an important pathogenic mechanism in many neurodegenerative diseases, including those caused by frontotemporal lobar degeneration (FTLD). There is a pressing need for scalable and mechanistically relevant blood markers of inflammation to facilitate drug development and experimental medicine. We assessed inflammatory profiles of serum cytokines from 214 patients with FTLD-associated syndromes (behavioural and language variants of frontotemporal dementia, progressive supranuclear palsy, corticobasal syndrome). We tested the association with brain microglial activation (by positron emission tomography) and survival. A pro-inflammatory profile across the FTLD spectrum (including TNF-α, TNF-R1, M-CSF, IL-17A, IL-12, IP-10 and IL-6) differentiated patients (all syndromes) from controls. A higher pro-inflammatory profile scores was associated with higher microglial activation in frontal and brainstem regions, and with lower survival. Blood-based markers of inflammation could increase the scalability and access to neuroinflammatory assessment of people with dementia, to facilitate clinical trials and experimental medicine studies.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S14)
Peripheral and central markers of inflammation increased in frontotemporal dementia and related conditions
Background: Neuroinflammation is an important pathogenic mechanism in frontotemporal dementia (FTD) and related disorders. Postmortem and in vivo imaging studies have shown brain inflammation early in these conditions, and as proportionate to symptom severity and rate of progression. However, data on inflammation blood markers of inflammation and their relationship with central inflammation are limited. Here we assess inflammatory patterns of 41 serum cytokines from patients with FTD and related conditions, and their association with regional microglial activation (TSPO PET).Method: Blood samples were obtained from 29 healthy controls, and 214 patients with a clinical diagnosis of behavioural variant FTD (bvFTD = 52), primary progressive aphasia (PPA = 51), progressive supranuclear palsy (PSP = 58) and corticobasal syndrome (CBS = 53). Serum assays used the MesoScale Discovery V‐Plex‐Human Cytokine 36 plex panel plus five additional cytokine assays. A Principal Component Analysis (PCA) across all participants was used to reduce dimensionality of cytokine data. A sub‐group of patients (bvFTD = 10, PPA = 17, PSP = 17) underwent PET imaging with [11C]PK11195 PET, as index of microglial activation. Kruskal‐Wallis and pairwise t‐tests were performed on the resulting components to compare each patient cohort to controls. [11C]PK11195 non‐displaceable binding potential (BPND) was calculated in 83 regions of interest (ROIs) across the whole brain. Spearman correlations tested associations between cytokine components and regional [11C]PK11195 BPND.Result: Sixteen cytokines were undetectable in >50% of participants and thus excluded. The first component identified by the PCA on the remaining 25 cytokines (explaining 19.7%) was strongly loaded by pro‐inflammatory cytokines (Figure 1, left). Kruskal–Wallis one‐way analyses of variance on detected significant differences across the groups (χ2(4) = 11.0, p = 0.027), and the pairwise t‐tests identified significant differences between each patient cohort and controls (Figure 1, right). Spearman correlations identified regional positive associations between individual cytokine‐component scores and microglial activation in frontal and brainstem regions across the whole group (R≥0.25), and syndrome‐specific regional patterns (Figure 2).Conclusion: This data‐driven approach identified a pro‐inflammatory profile across FTD and related conditions, which is positively associated with higher levels of microglial activation in syndrome‐related key brain regions. Blood‐based tests could greatly increase the scalability and access to neuroinflammatory assessment in dementia and experimental medicine studies.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S14)
Open AccessPeripheral and central markers of inflammation increased in frontotemporal dementia and related conditions
Background: Neuroinflammation is an important pathogenic mechanism in frontotemporal dementia (FTD) and related disorders. Postmortem and in vivo imaging studies have shown brain inflammation early in these conditions, and as proportionate to symptom severity and rate of progression. However, data on inflammation blood markers of inflammation and their relationship with central inflammation are limited. Here we assess inflammatory patterns of 41 serum cytokines from patients with FTD and related conditions, and their association with regional microglial activation (TSPO PET).Method: Blood samples were obtained from 29 healthy controls, and 214 patients with a clinical diagnosis of behavioural variant FTD (bvFTD = 52), primary progressive aphasia (PPA = 51), progressive supranuclear palsy (PSP = 58) and corticobasal syndrome (CBS = 53). Serum assays used the MesoScale Discovery V‐Plex‐Human Cytokine 36 plex panel plus five additional cytokine assays. A Principal Component Analysis (PCA) across all participants was used to reduce dimensionality of cytokine data. A sub‐group of patients (bvFTD = 10, PPA = 17, PSP = 17) underwent PET imaging with [11C]PK11195 PET, as index of microglial activation. Kruskal‐Wallis and pairwise t‐tests were performed on the resulting components to compare each patient cohort to controls. [11C]PK11195 non‐displaceable binding potential (BPND) was calculated in 83 regions of interest (ROIs) across the whole brain. Spearman correlations tested associations between cytokine components and regional [11C]PK11195 BPND.Result: Sixteen cytokines were undetectable in >50% of participants and thus excluded. The first component identified by the PCA on the remaining 25 cytokines (explaining 19.7%) was strongly loaded by pro‐inflammatory cytokines (Figure 1, left). Kruskal–Wallis one‐way analyses of variance on detected significant differences across the groups (χ2(4) = 11.0, p = 0.027), and the pairwise t‐tests identified significant differences between each patient cohort and controls (Figure 1, right). Spearman correlations identified regional positive associations between individual cytokine‐component scores and microglial activation in frontal and brainstem regions across the whole group (R≥0.25), and syndrome‐specific regional patterns (Figure 2).Conclusion: This data‐driven approach identified a pro‐inflammatory profile across FTD and related conditions, which is positively associated with higher levels of microglial activation in syndrome‐related key brain regions. Blood‐based tests could greatly increase the scalability and access to neuroinflammatory assessment in dementia and experimental medicine studies.
- Open Access
- 24 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S10)
Peripheral and central markers of inflammation increased in frontotemporal dementia and related conditions
Background: Neuroinflammation is an important pathogenic mechanism in frontotemporal dementia (FTD) and related disorders. Postmortem and in vivo imaging studies have shown brain inflammation early in these conditions, and as proportionate to symptom severity and rate of progression. However, data on inflammation blood markers of inflammation and their relationship with central inflammation are limited. Here we assess inflammatory patterns of 41 serum cytokines from patients with FTD and related conditions, and their association with regional microglial activation (TSPO PET).Method: Blood samples were obtained from 29 healthy controls, and 214 patients with a clinical diagnosis of behavioural variant FTD (bvFTD = 52), primary progressive aphasia (PPA = 51), progressive supranuclear palsy (PSP = 58) and corticobasal syndrome (CBS = 53). Serum assays used the MesoScale Discovery V‐Plex‐Human Cytokine 36 plex panel plus five additional cytokine assays. A Principal Component Analysis (PCA) across all participants was used to reduce dimensionality of cytokine data. A sub‐group of patients (bvFTD = 10, PPA = 17, PSP = 17) underwent PET imaging with [11C]PK11195 PET, as index of microglial activation. Kruskal‐Wallis and pairwise t‐tests were performed on the resulting components to compare each patient cohort to controls. [11C]PK11195 non‐displaceable binding potential (BPND) was calculated in 83 regions of interest (ROIs) across the whole brain. Spearman correlations tested associations between cytokine components and regional [11C]PK11195 BPND.Result: Sixteen cytokines were undetectable in >50% of participants and thus excluded. The first component identified by the PCA on the remaining 25 cytokines (explaining 19.7%) was strongly loaded by pro‐inflammatory cytokines (Figure 1, left). Kruskal–Wallis one‐way analyses of variance on detected significant differences across the groups (χ2(4) = 11.0, p = 0.027), and the pairwise t‐tests identified significant differences between each patient cohort and controls (Figure 1, right). Spearman correlations identified regional positive associations between individual cytokine‐component scores and microglial activation in frontal and brainstem regions across the whole group (R≥0.25), and syndrome‐specific regional patterns (Figure 2).Conclusion: This data‐driven approach identified a pro‐inflammatory profile across FTD and related conditions, which is positively associated with higher levels of microglial activation in syndrome‐related key brain regions. Blood‐based tests could greatly increase the scalability and access to neuroinflammatory assessment in dementia and experimental medicine studies.
- 24 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S10)
Open AccessPeripheral and central markers of inflammation increased in frontotemporal dementia and related conditions
Background: Neuroinflammation is an important pathogenic mechanism in frontotemporal dementia (FTD) and related disorders. Postmortem and in vivo imaging studies have shown brain inflammation early in these conditions, and as proportionate to symptom severity and rate of progression. However, data on inflammation blood markers of inflammation and their relationship with central inflammation are limited. Here we assess inflammatory patterns of 41 serum cytokines from patients with FTD and related conditions, and their association with regional microglial activation (TSPO PET).Method: Blood samples were obtained from 29 healthy controls, and 214 patients with a clinical diagnosis of behavioural variant FTD (bvFTD = 52), primary progressive aphasia (PPA = 51), progressive supranuclear palsy (PSP = 58) and corticobasal syndrome (CBS = 53). Serum assays used the MesoScale Discovery V‐Plex‐Human Cytokine 36 plex panel plus five additional cytokine assays. A Principal Component Analysis (PCA) across all participants was used to reduce dimensionality of cytokine data. A sub‐group of patients (bvFTD = 10, PPA = 17, PSP = 17) underwent PET imaging with [11C]PK11195 PET, as index of microglial activation. Kruskal‐Wallis and pairwise t‐tests were performed on the resulting components to compare each patient cohort to controls. [11C]PK11195 non‐displaceable binding potential (BPND) was calculated in 83 regions of interest (ROIs) across the whole brain. Spearman correlations tested associations between cytokine components and regional [11C]PK11195 BPND.Result: Sixteen cytokines were undetectable in >50% of participants and thus excluded. The first component identified by the PCA on the remaining 25 cytokines (explaining 19.7%) was strongly loaded by pro‐inflammatory cytokines (Figure 1, left). Kruskal–Wallis one‐way analyses of variance on detected significant differences across the groups (χ2(4) = 11.0, p = 0.027), and the pairwise t‐tests identified significant differences between each patient cohort and controls (Figure 1, right). Spearman correlations identified regional positive associations between individual cytokine‐component scores and microglial activation in frontal and brainstem regions across the whole group (R≥0.25), and syndrome‐specific regional patterns (Figure 2).Conclusion: This data‐driven approach identified a pro‐inflammatory profile across FTD and related conditions, which is positively associated with higher levels of microglial activation in syndrome‐related key brain regions. Blood‐based tests could greatly increase the scalability and access to neuroinflammatory assessment in dementia and experimental medicine studies.